Adding Bortezomib to DRC Does Not Improve PFS in Waldenström Macroglobulinemia
Researchers sought to determine whether adding bortezomib to DRC would improve survival in patients with Waldenström macroglobulinemia.
Researchers sought to determine whether adding bortezomib to DRC would improve survival in patients with Waldenström macroglobulinemia.
Researchers sought to determine the clinical, therapy, and outcome patterns of patients with WM in Latin America.
Researchers sough to determine whether zanubrutinib would improve responses compared with ibrutinib in patients with Waldenström macroglobulinemia.
Researchers sought to determine whether venetoclax would be safe and effective in patients with previously treated Waldenström macroglobulinemia.
Researchers described a case study that suggested ibrutinib may have beneficial effects in patients with acquired von Willebrand syndrome that is secondary to Waldenström macroglobulinemia.
Researchers sought to determine whether fixed-duration chemotherapy-free treatment with obinutuzumab and idelalisib would be effective in patients with R/R WM.
The FDA has accepted a supplemental new drug application (sNDA) for brukinsa for the treatment of adults with Waldenström Macroglobulinemia (WM).
A year-end update on WM, a distinct entity of lymphoplasmacytic lymphoma presenting with monoclonal pleomorphic immunoglobulin M (IgM) proteins, was recently published in the American Journal of Hematology.
A case report detailed reinfection with SARS-CoV-2 in an immunocompromised patient with Waldenström macroglobulinemia.
Among a subset of patients with previously treated Waldenström macroglobulinemia, ibrutinib is highly active and may lead to long-term disease control.